Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer Bone Pain at ICRS Symposium

SOLANA BEACH, Calif., July 01, 2024 – Artelo Biosciences, Inc. (Nasdaq: ARTL), a pharmaceutical company in its clinical stage, is currently focusing on the development of treatments directed at modulating lipid-signaling pathways for conditions including cancer, pain, dermatologic, and neurological disorders. Recently, Professor Saoirse O’Sullivan, who serves as the Vice President of Translational Sciences at Artelo, showcased preclinical findings concerning ART26.12, the company’s innovative fatty acid binding protein 5 (FABP5) inhibitor. This presentation took place at the 34th Annual International Cannabinoid Research Society (ICRS) Symposium in Salamanca, Spain, from June 30 to July 5, 2024.

The presentation titled “ART26.12, a Novel Fatty Acid-Binding Protein 5 Inhibitor, Shows Efficacy in Breast Cancer-Induced Bone Pain,” detailed the promising results of ART26.12 in mitigating pain behaviors triggered by breast cancer in preclinical models. The data is the latest in a series of four preclinical pain studies that have demonstrated similar positive outcomes with ART26.12. Importantly, the effective doses and plasma exposures observed in the breast cancer bone pain study align with previously released data on ART26.12 regarding oxaliplatin-induced peripheral neuropathy.

Professor Saoirse O’Sullivan elaborated on the continuing success of ART26.12 in preclinical trials, highlighting its potential as a novel, non-opioid, and non-steroidal analgesic treatment. The consistent efficacy and appropriate dosing levels of ART26.12 across various animal models of pain, whether induced by cancer, diabetes, or different chemotherapies, have been particularly noteworthy. Looking ahead, Artelo anticipates moving into human clinical trials for ART26.12, pending the acceptance of their Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA).

Breast cancer remains the most prevalent cancer among women, with bone being the most common site for metastasis in advanced stages. Over half of the patients with advanced breast cancer develop bone metastasis, leading to severe complications such as intense pain, fractures, and spinal cord compression. ART26.12, a selective and potent FABP5 inhibitor developed by Artelo, offers a novel treatment approach for cancer-related pain, an area where effective therapies with minimal side effects are scarce.

ART26.12 is Artelo’s lead candidate in a series of fatty acid binding protein (FABP) inhibitors. FABPs are intracellular proteins that facilitate the transport of lipids, such as endocannabinoids and fatty acids. The overexpression of FABPs is linked to disrupted lipid signaling in various pathological conditions. As a potent and selective inhibitor of FABP5, ART26.12 is being developed as a peripheral, non-opioid, non-steroidal analgesic, with initial clinical trials aimed at addressing chemotherapy-induced peripheral neuropathy (CIPN). Beyond CIPN, ART26.12 and other compounds from Artelo’s comprehensive collection of small molecule FABP inhibitors show therapeutic potential for treating specific cancers, neuropathic and nociceptive pain, and anxiety disorders.

The International Cannabinoid Research Society (ICRS) is a leading global scientific body encompassing over 650 researchers from 40 countries, all dedicated to studying endogenous, plant-derived, and synthetic cannabinoids and related bioactive lipids. The primary mission of the ICRS is to facilitate an open forum for researchers to discuss their findings and to provide unbiased information on cannabis and cannabinoids.

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing proprietary treatments that influence lipid-signaling pathways, including the endocannabinoid system. The company has a diverse portfolio of product candidates designed to meet significant unmet medical needs across various diseases and conditions, including anorexia, cancer, anxiety, pain, and inflammation. Artelo is led by experienced biopharmaceutical executives and collaborates with esteemed researchers and technology experts to develop high-impact therapies.